Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jul 1;216(1):29-35.
doi: 10.1093/infdis/jix110.

Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine for the Prevention of Malaria Among HIV-Infected Pregnant Women

Paul Natureeba  1 , Abel Kakuru  1 , Mary Muhindo  1 , Teddy Ochieng  1 , John Ategeka  1 , Catherine A Koss  2 , Albert Plenty  2 , Edwin D Charlebois  3 , Tamara D Clark  2 , Bridget Nzarubara  1 , Miriam Nakalembe  4 , Deborah Cohan  5 , Gabrielle Rizzuto  6 , Atis Muehlenbachs  7 , Theodore Ruel  8 , Prasanna Jagannathan  2 , Diane V Havlir  2 , Moses R Kamya  9 , Grant Dorsey  2
Affiliations
Randomized Controlled Trial

Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine for the Prevention of Malaria Among HIV-Infected Pregnant Women

Paul Natureeba et al. J Infect Dis. .

Abstract

Background: Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-treated nets remain the main interventions for prevention of malaria in human immunodeficiency virus (HIV)-infected pregnant women in Africa. However, antifolate and pyrethroid resistance threaten the effectiveness of these interventions, and new ones are needed.

Methods: We conducted a double-blinded, randomized, placebo-controlled trial comparing daily TMP-SMX plus monthly dihydroartemisinin-piperaquine (DP) to daily TMP-SMX alone in HIV-infected pregnant women in an area of Uganda where indoor residual spraying of insecticide had recently been implemented. Participants were enrolled between gestation weeks 12 and 28 and given an insecticide-treated net. The primary outcome was detection of active or past placental malarial infection by histopathologic analysis. Secondary outcomes included incidence of malaria, parasite prevalence, and adverse birth outcomes.

Result: All 200 women enrolled were followed through delivery, and the primary outcome was assessed in 194. There was no statistically significant difference in the risk of histopathologically detected placental malarial infection between the daily TMP-SMX plus DP arm and the daily TMP-SMX alone arm (6.1% vs. 3.1%; relative risk, 1.96; 95% confidence interval, .50-7.61; P = .50). Similarly, there were no differences in secondary outcomes.

Conclusions: Among HIV-infected pregnant women in the setting of indoor residual spraying of insecticide, adding monthly DP to daily TMP-SMX did not reduce the risk of placental or maternal malaria or improve birth outcomes.

Clinical trials registration: NCT02282293.

Keywords: HIV; dihydroartemisinin-piperaquine; malaria; pregnancy; trimethoprim-sulfamethoxazole.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trial profile. Abbreviations: DP, dihydroartemisinin-piperaquine; HIV, human immunodeficiency virus; TMP-SMX, trimethoprim-sulfamethoxazole.
Figure 2.
Figure 2.
Risk of any placental malarial infection detection by histopathologic analysis among study participants, stratified by gravidity. Black bars denote the arm that received trimethoprim-sulfamethoxazole (TMP-SMX) daily. Gray bars denote the arm that received TMP-SMX daily and dihydroartemisinin-piperaquine monthly. Error bars indicate upper limits of 95% confidence intervals.
See this image and copyright information in PMC

Comment in

References

    1. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007; 7:93–104. - PubMed
    1. Flateau C, Le Loup G, Pialoux G. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis 2011; 11:541–56. - PubMed
    1. Ned RM, Moore JM, Chaisavaneeyakorn S, Udhayakumar V. Modulation of immune responses during HIV-malaria co-infection in pregnancy. Trends Parasitol 2005; 21:284–91. - PubMed
    1. ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004; 71(2 Suppl):41–54. - PubMed
    1. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. Recommendatinos for a public health approach http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf Accessed December 2016.

Publication types

Associated data